CA9 and neoplasm: The carbonic anhydrase enzyme, CAIX, is upregulated via HIF-1α and a significant prognostic marker in RCC; a preclinical study of anti-CAIX antibodies (girentuximab) was shown to stimulate both innate and adaptive immune-mediated killing of tumor cells [65].